Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E31.09 EPS (ttm)1.97 Insider Own0.04% Shs Outstand2.77B Perf Week-1.74%
Market Cap169.02B Forward P/E15.74 EPS next Y3.88 Insider Trans-45.15% Shs Float2.75B Perf Month3.89%
Income5.49B PEG5.01 EPS next Q0.89 Inst Own74.40% Short Float0.81% Perf Quarter-2.23%
Sales39.91B P/S4.24 EPS this Y-61.60% Inst Trans-0.58% Short Ratio2.09 Perf Half Y8.59%
Book/sh15.82 P/B3.86 EPS next Y2.83% ROA5.60% Target Price68.00 Perf Year20.11%
Cash/sh4.76 P/C12.84 EPS next 5Y6.21% ROE12.50% 52W Range46.83 - 65.46 Perf YTD18.56%
Dividend1.88 P/FCF251.90 EPS past 5Y41.50% ROI6.40% 52W High-6.61% Beta0.78
Dividend %3.08% Quick Ratio1.60 Sales past 5Y-3.00% Gross Margin64.50% 52W Low30.55% ATR1.18
Employees68000 Current Ratio1.90 Sales Q/Q4.60% Oper. Margin19.60% RSI (14)45.73 Volatility1.28% 1.61%
OptionableYes Debt/Eq0.57 EPS Q/Q21.80% Profit Margin13.80% Rel Volume0.75 Prev Close60.76
ShortableYes LT Debt/Eq0.54 EarningsOct 25 BMO Payout92.90% Avg Volume10.60M Price61.13
Recom2.40 SMA20-1.33% SMA50-1.14% SMA2005.79% Volume7,987,000 Change0.61%
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Dec-04-16 08:00AM  Merck CEO Ken Frazier Is A Quote Machine at Forbes
Dec-03-16 09:43AM  Why Bristol-Myers Squibb Co. Stock Surged in November at Motley Fool
Dec-02-16 03:05PM  Tech Datas board gets more diverse with addition of former Merck executive at bizjournals.com
01:17PM  Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda at Insider Monkey
11:04AM  AbbVies Venclexta May Become Promising Multiple Myeloma Therapy
10:04AM  Acute Myeloid Leukemia: Growth Opportuny for AbbVies Venclexta?
09:52AM  Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
08:57AM  Merck KGaA (MKGAF) Expands Distribution Deal with Roche
08:04AM  Keytruda Is Mercks Immuno-Oncology Business
08:04AM  Label Expansion May Boost Venclextas Growth Prospects
06:40AM  Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
Dec-01-16 03:56PM  Pharma execs weigh in on possible changes under Trump Reuters
11:05AM  Recent R&D Developments from Merck You Wont Want to Miss
11:04AM  Whats Forcing Valeant to Sell Its Core Assets?
10:55AM  Bringing foreign drugs into the US market is a dangerous ...
10:39AM  Alexandria Real Estate, Merck Ink Long-Term Pharma Lease
10:04AM  AbbVies Plans for ABT-555, a Novel Multiple Sclerosis Therapy
09:08AM  Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
08:10AM  Analysts Top Pharmaceutical Buys Offer Big Dividends and Growth Potential at 24/7 Wall St.
08:05AM  Inside Mercks Business Segment-Wise Performance
08:04AM  AbbVie Is Focused on Growth Opportunities in Neuroscience Space
08:04AM  Pfizers Profitability and Financial Guidance
07:48AM  3 Ways Organovo Holdings, Inc. Plans to Grow Exponentially for Years to Come at Motley Fool
07:39AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : December 1, 2016
07:00AM  FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Mercks KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Business Wire
Nov-30-16 09:37PM  Five Dow Jones Stocks That Can Outperform The Market at Insider Monkey
11:04AM  These Pfizer Products Saw Falling Revenues in 3Q16
11:04AM  Mercks Zepatier Put Pricing Pressure on Gilead Sciencess Harvoni
10:05AM  AbbVies HCV Regimen Gets Breakthrough Therapy Designation
10:04AM  Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids
10:04AM  Scrutinizing the HCV Market Based on Genotypes
08:38AM  Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
08:34AM  Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
08:33AM  J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
08:05AM  AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017
08:05AM  Steady Rise: Allergans International Segment in 3Q16
08:04AM  Phase 3 Trials Show Elagolixs Efficacy for Endometriosis Pain
08:04AM  Could There Be a Steep Fall for Gilead Sciencess HCV Franchise?
07:11AM  Merck selects Alexandria Real Estate to develop research facility
07:00AM  New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies Business Wire
Nov-29-16 05:04PM  Next-Generation Hepatitis C Therapy May Be AbbVies Growth Driver
05:04PM  Falling Revenue in Allergans US General Medicines Segment
04:04PM  New Indications May Be Big Opportunity for AbbVies Imbruvica
03:51PM  Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout
11:04AM  Elagolix May Become a Leading Uterine Fibroids Drug
10:04AM  Elagolix May Become a Strong Growth Driver for AbbVie
10:04AM  The US is Gilead Sciencess Major Market
09:17AM  Injections, implants tested as new weapons to prevent HIV
08:06AM  German Merck, Pfizer get FDA priority review for cancer drug Reuters
07:00AM  Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action. Business Wire
Nov-28-16 04:19PM  Which companies will benefit from Cuban biotech?
09:38AM  FDA Grants Merck Priority Review for Keytruda Drug (MRK) at Investopedia
08:05AM  Is Gilead Sciences Stock Oversold?
08:04AM  How Did Bristol-Myers Squibbs Blockbuster Oncology Drug Perform?
07:57AM  J&J (JNJ) Confirms it Approached Actelion for Possible Deal
07:52AM  Early movers: AMZN, M, WMT, TGT, JWN, BA, MRK, DIS, WFC, T & more at CNBC
07:00AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer Business Wire
12:11AM  [$$] Amazon Broadens Cloud Services as Big Companies Sign On at The Wall Street Journal
12:08AM  [$$] Amazon Broadens Cloud Services as Big Companies Sign On at The Wall Street Journal
Nov-25-16 11:09PM  [$$] House GOP Business-Tax Plan Upends U.S. Policy, Bares Corporate Fault Lines at The Wall Street Journal
02:26PM  [$$] Kymab Raises $100 Million for Antibody-Drug Technology at The Wall Street Journal
12:13PM  Blue Chips Hold Narrow Lead In Stock Market; Oil Takes Hit
09:40AM  How Does Bristol-Myers Squibbs Valuation Compare to Peers?
08:56AM  Merck's New Drugs, Cost Management to Fuel Growth in 2017
08:15AM  Better Buy: Celgene Corporation vs. Merck & Co. at Motley Fool
07:00AM  Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov-24-16 11:04AM  Patent Litigations to Delay Tevas New Product Launches
10:04AM  A Deeper Look into Eli Lillys New Products Portfolio
09:37AM  [$$] House GOP Business-Tax Plan Upends U.S. Policy, Bares Fault Lines at The Wall Street Journal
Nov-23-16 07:27PM  Lilly Leads Medical Stocks Lower, But This IBD 50 Stock Broke Out
05:06PM  [$$] Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge at The Wall Street Journal
04:28PM  Merck Bumps Its Dividend Higher at Investopedia
04:07PM  Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down
02:49PM  Five Lessons From Today's Pharma Failures at Forbes
12:26PM  Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive
09:45AM  Stocks Open Lower; Deere Soars, Eli Lilly Crumbles
09:15AM  Merck Declares 47-Cent Quarterly Dividend (MRK) at Investopedia
08:14AM  Merck Announces Dividend Increase, Offering Attractive Yield (MRK) at Investopedia
Nov-22-16 11:53PM  [$$] Crisis Consultant Writes Novels to Recharge at The Wall Street Journal
06:49PM  Is Merck & Co., Inc. (MRK) A Good Stock To Buy? at Insider Monkey
06:04PM  These Will Be the Challenges to BMYs Opdivo in the Lung Cancer Space
01:22PM  Merck Announces Increased Quarterly Dividend Business Wire
12:20PM  ETFs with exposure to Merck & Co., Inc. : November 22, 2016
11:54AM  Where Does Eli Lillys Valuation Stand Next to Peers?
11:04AM  What Do the Analysts Recommend for Bristol-Myers Squibbs Stock?
11:00AM  [$$] Crisis Consultant Writes Novels to Recharge at The Wall Street Journal
10:04AM  Inside Bristols Key to Success: Multiple Labels for Opdivo
08:04AM  Bristols Opdivo Has One Eye on Advanced Bladder Cancer
08:00AM  What Trump isn't saying about drugmakers matters to investors at CNBC
07:00AM  New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology Business Wire
03:56AM  AstraZeneca cleared to resume enrolment in cancer drug trials Reuters
Nov-21-16 04:28PM  Share buybacks will return with a vengeance next year at MarketWatch
01:24PM  Bullish On Trump-led America, Druckenmiller Sells Gold, Bets On Economy at Insider Monkey
11:40AM  'Unicorn' Intarcia files U.S. approval for diabetes implant Reuters
11:04AM  Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?
10:04AM  Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
08:46AM  $13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market at Motley Fool
08:04AM  Yes, Its a Similar Label for Opdivo and Tecentriq in Lung Cancer
07:20AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : November 21, 2016
Nov-20-16 12:13PM  Can Bristol-Myers Squibb's Dividend Even Survive? at Motley Fool
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has a collaboration agreement with Adaptimmune Therapeutics plc; and a research agreement with Proteros Biostructures to develop small molecule compounds for the treatment of various cancers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM